Development of chromatographic methods for the determination of genotoxic impurities in cloperastine fendizoate

Journal of Pharmaceutical and Biomedical Analysis

Volumn 61, Issue , 2012, Pages 230-236

  García, Antonia ^a   Rupérez, Francisco J ^a   Ceppa, Florencia ^a,b   Pellati, Federica ^b   Barbas, Coral ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Alkyl halides; Cloperastine fendizoate; GC; Genotoxic impurities; HPLC; Limit test; Sulfonate esters; Threshold of toxicological concern

Indexed keywords

2 CHLOROETHANOL; 2 CHLOROETHYL 4 TOLUENESULFONATE; ANTITUSSIVE AGENT; CLOPERASTINE FENDIZOATE; ESTER DERIVATIVE; METHANOL; METHYL 4 TOLUENESULFONATE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; WATER;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; DRUG IMPURITY; GAS CHROMATOGRAPHY; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF DETECTION; MASS SPECTROMETRY; PH; PLASMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MUTAGENICITY TESTS; PIPERIDINES;

EID: 84856117000     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.12.014     Document Type: Article

References (18)

1. Catania M.A., Cuzzocrea S. Pharmacological and clinical overview of cloperastine in treatment of cough. Ther. Clin. Risk Manage. 2011, 7:83-92.
2. Elder D.P., Snodin D.J. Drug substance presented as sulfonic acid salts: overview of utility, safety and regulation. J. Pharm. Pharmacol. 2009, 61:269-278.
3. Liu D.Q., Sun M., Kord A.S. Recent advances in trace analysis of pharmaceutical genotoxic impurities. J. Pharm. Biomed. Anal. 2010, 51:999-1014.
4. Teasdale A., Eyley S.C., Delaney E., Jacq K., Taylor-Worth K., Lipczynski A., Reif V., Elder D.P., Facchine K.L., Golec S., Oestrich R.S., Sandra P., David F. Mechanism and processing parameters affecting the formation of methyl methanesulfonate from methanol and methanesulfonic acid: an illustrative example for sulfonate ester impurity formation. Org. Process Res. Dev. 2009, 13:429-433.
5. Teasdale A., Delaney E., Eyley S.C., Jacq K., Taylor-Worth K., Lipczynski A., Hoffmann W., Reif V., Elder D.P., Facchine K.L., Golec S., Oestrich R.S., Sandra P., David F. A detailed study of sulfonate ester formation and solvolysis reaction rates and application toward establishing sulfonate ester control in pharmaceutical manufacturing processes. Org. Process Res. Dev. 2010, 14:999-1007.
6. Snodin D.J. Residues of genotoxic alkyl mesylates in mesylate salt drug substance: real or imaginary problems?. Regul. Toxicol. Pharmacol. 2006, 45:79-90.
7. Sobol Z., Engel M.E., Rubitzki E., Ku W.W., Aubrecht J., Schiestl R.H. Genotoxic profiles of common alkyl halides and esters with alkylating activity. Mutat. Res. 2007, 633:80-94.
8. Elder D.P., Teasdale A., Lipczynski A.M. Control and analysis of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs). J. Pharm. Biomed. Anal. 2008, 46:1-8.
9. Elder D.P., Lipczynski A.M., Teasdale A. Control and analysis of alkyl and benzyl halides and other reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs). J. Pharm. Biomed. Anal. 2008, 48:497-507.
10. Giordani A., Kobel W., Gally H.U. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process. Eur. J. Pharm. Sci. 2011, 43:1-15.
11. Raman N.V.V.S.S., Prasad A.V.S.S., Ratnakar Reddy K. Strategies for the identification, control and determination of genotoxic impurities in drug substance: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 2011, 55:662-667.
12. European Medicines Agency, Committee for Medicinal Products for Human Use, Guideline on the limits of genotoxic impurities, CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006, 2006.
13. Delaney E.J. An impact analysis of the application of the threshold of toxicological concern concept to pharmaceuticals. Regul. Toxicol. Pharmacol. 2007, 49:107-124.
14. Husegawa C., Kumazawa T., Lee X.-P., Fujishiro M., Kuriki A., Marumo A., Seno H., Sato K. Simultaneous determination of ten antihistamine drugs in human plasma using pipette tip solid-phase extraction and gas chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20:537-543.
15. Li H., Zhang C., Wang J., Jiang Y., Fawcett J.P., Gu J. Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2010, 51:716-722.
16. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH), Guideline Q2(R1)-Validation of Analytical Procedures: Text and Methodology, 2005.
17. Taylor G.E., Gosling M., Pearce A. Low level determination of p-toluensulfonate and benzenesulfonate esters in drug substance by high performance liquid chromatography/mass spectrometry. J. Chromatogr. A 2006, 1119:231-237.
18. Kakadiya P.R., Pratapa Reddy B., Singh V., Ganguly S., Chandrashekhar T.G., Singh D.K. Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir active pharmaceutical ingredients by LC/MS/MS using electrospray ionization. J. Pharm. Biomed. Anal. 2011, 55:379-384.